To access the localized content, select the website associated with the Division of your interest:

Health & Safety

    Healthcare & Life Sciences

      Energy & Mobility

        Investor Relations

        Press Releases

        Press releases

        1. GVS Share buyback information
        2. GVS: 2022 Corporate Events Calendar
        3. GVS Share buyback information

        1. 3F Buyback Dicember 2021
        2. GVS Share buyback information
        3. GVS Share buyback information
        4. GVS Acquires 100% of the Shanghai Transfusion Technology Co., LTD.
          Price Sensitive
        5. GVS Share buyback information
        6. GVS Share buyback information
        7. 3F Buyback November 2021
        8. GVS Share buyback information
        9. GVS Share buyback information
        10. GVS Share buyback information
        11. Notice of Publication of Documents
        12. GVS Approves consolidated results to 30 September 2021
          Price Sensitive
        13. GVS Share buyback information
        14. 3F Buyback October 2021
        15. GVS Share buyback information
        16. GVS Share buyback information
        17. GVS Share buyback information
        18. GVS Launches treasury share buyback programme
          Price Sensitive
        19. GVS approves consolidated results to 30 June 2021 revenues up 29.7%, EBITDA margin at 37.9%
          Price Sensitive
        20. GVS acquires 100% of the RPB Group, an American player specialised in the design and production of respiratory protection devices, and completes its product range in the world of professional masks
          Price Sensitive
        21. GVS approves consolidated results as at 31 March 2021
          Price Sensitive
        22. The GVS Board of Directors approves the 2020 financial statement: revenues up 60%, strong growth in Group profitability and solid increase in all key economic and financial indicators
          Price Sensitive
        23. GVS S.p.A. – Financial Calendar 2021
          Price Sensitive

        1. GVS approves the consolidated results at 30 September 2020 revenue up 49.6% and marked growth of the Group’s profit margin
          Price Sensitive
        2. The bod of GVS S.p.A. Approves the first half 2020 results revenue at 30 June 2020 up 25% and considerable growth in profit margin
          Price Sensitive
        3. GVS: completion of the Closing of the acquisition of Haemonetics Puerto Rico, LLC
          Price Sensitive
        4. GVS S.p.A. – Financial Calendar 2020
          Price Sensitive
        5. GVS announces the agreement to acquire Puerto Rico-based manufacturing operations of Haemonetics

        This website uses first-party and third-party cookies in order to offer dynamic content and a better user experience. For further information please read our Privacy Policy.